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ABSTRACT 
 
Background: Cardiac-enriched microRNAs (miRNAs) are released into the 
circulation following ST-elevation myocardial infarction (STEMI). Lack of 
standardized approaches for reverse transcription quantitative real time polymerase 
chain reaction (RT-qPCR) data normalisation and presence of RT-qPCR inhibitors 
(e.g. heparin) in patient blood samples have prevented reproducible miRNA 
quantification in this cohort and subsequent translation of these biomarkers to clinical 
practice.   
Methods: Using a RT-qPCR miRNA screening platform we identified and validated 
an endogenous circulating miRNA as a normalisation control. In addition, we 
assessed the effects of in vivo and in vitro anticoagulant drugs administration 
(heparin and bivalirudin) on three RT-qPCR normalisation strategies [global miRNA 
mean, exogenous spike-in control (cel-miR-39), and endogenous miRNA control].  
Finally, we evaluated the effect of heparin and its in vitro inhibition with heparinase 
on the quantification of cardiac-enriched miRNAs in STEMI patients.  
Results: miR-425-5p was validated as an endogenous miRNA control. Heparin 
administration in vitro and in vivo inhibited all RT-qPCR normalisation strategies. In 
contrast, bivalirudin had no effects on cel-miR-39 or miR-425-5p quantification. In 
vitro RNA sample treatment with 0.3U of heparinase overcame heparin-induced 
overestimation of cardiac-enriched miRNA levels and improved their correlation with 
high-sensitivity troponin T.    
Conclusion: MicroRNA quantification in STEMI patients receiving heparin is 
jeopardised by its effect on all RT-qPCR normalisation approaches. Use of samples 
from bivalirudin-treated patients or in vitro treatment of heparin-contaminated 
samples with heparinase are suitable alternatives for miRNA quantification in this 
cohort. Finally, we reinforce the evidence that cardiac-enriched miRNAs early after 
myocardial reperfusion reflect the severity of cardiac injury.  
 
Keywords: microRNA; RT-qPCR normalisation; heparin; bivalirudin; myocardial 
infarction 
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1. Introduction  
Coronary artery disease (CAD) is the leading cause of mortality worldwide (1). Its 
most serious manifestation, ST elevation myocardial infarction (STEMI), is 
characterized by irreversible myocardial injury due to prolonged ischaemia (1). 
Although cardiac troponins are established biochemical markers of STEMI, 
methodological limitations in their quantification (2) and only moderate correlations 
with infarct size (3) prompt the identification of new markers of cardiac injury.  
In the last decade, microRNAs (miRNAs), small non-coding RNAs of approximately 
22 – 23 nucleotides in length, have emerged as potential disease markers given their 
successful isolation from biological fluids and notable resistance to degradation (4-
7). In the context of STEMI, many studies have reported deregulated plasmatic 
levels of several miRNAs (8). Amongst these, cardiac-enriched miRNAs have been 
shown to be up-regulated early after the onset of STEMI and are of particular interest 
as they are more likely to inform about the nature and extent of myocardial injury (8). 
Nonetheless, lack of consensus regarding real time quantitative polymerase chain 
reaction (RT-qPCR) data normalisation and presence of RT-qPCR inhibitors, such 
as heparin, in STEMI patient samples contribute to inconsistencies among studies 
and represent critical limitations for the translation of miRNAs to daily clinical practice 
(8, 9).  
RT-qPCR is the current preferred method for miRNA quantification due to its 
accuracy, specificity, and broad dynamic range (10). Data normalisation is a 
fundamental step to minimize the effects of systematic errors and obtain biologically 
meaningful miRNA expression in RT-qPCR studies (10). The most common 
normalisation strategy is the use of a stably expressed endogenous control. 
Nonetheless, there are no circulating miRNAs that have been systematically 
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validated as endogenous controls in STEMI patients to date. As an alternative, 
synthetic miRNAs, especially Caenorhabditis elegans miR-39 (cel-miR-39), have 
been used as normalisation controls in most studies (8). However, heparin, routinely 
administered during coronary intervention such as primary percutaneous coronary 
intervention (PPCI), has been shown to affect cel-miR-39 detection by RT-qPCR, 
which might compromise its use as a normalisation control (11-13). Another 
proposed normalisation approach is to use the average expression of quantified 
miRNAs, based on the premise that the mean expression of hundreds to thousands 
of quantified miRNAs is not altered by deregulation of few miRNAs or miRNA 
clusters between cases and controls (14).  Yet, this strategy is not feasible for clinical 
routine or large clinical studies focusing on few target miRNAs.  Furthermore, the 
effect of heparin on the global miRNA expression is also not known. Therefore, 
circulating miRNA quantification in STEMI patients undergoing PPCI remains an 
unmet challenge. This study aimed to (i) identify and validate an endogenous 
circulating miRNA control in STEMI patients; (ii) assess the effects of anticoagulant 
drugs, such as heparin and bivalirudin, on currently used RT-qPCR normalisation 
approaches; and (iii) evaluate the effect of in vitro heparin inhibition with heparinase 
on the quantification of circulating cardiac-enriched miRNAs in STEMI patients.   
2. Materials and Methods 
2.1.  Study cohort and design 
Patient recruitment was performed at the Freeman Hospital, Newcastle upon Tyne, 
United Kingdom. Only patients presenting within 6 hours of chest pain onset which 
met electrocardiographic criteria of STEMI, as well as angiographic evidence of a 
large (≥3mm calibre) and acutely occluded (TIMI flow 0/1) coronary artery 
undergoing PPCI were included. This study was approved by the local ethics 
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committee and verbal consent was obtained once patients met inclusion criteria, 
followed by written consent post procedure (REC reference: NE/14/1070; EudraCT 
number: 2014-002628-29). Plasma samples were collected from 73 STEMI patients 
prior to and at multiple time points following myocardial reperfusion. Patients 
received an intravenous bolus of unfractionated heparin (70 units/kg, n = 70) or 
bivalirudin (0.75 mg/kg, n = 3) prior to PPCI, which preceded collection of the first 
blood sample. In addition, plasma samples from healthy individuals (n = 6) and 
patients with stable CAD (n = 6) were used as controls.  
The study was conducted in 3 consecutive phases (Figure 1). During phase 1, 
screening of 179 miRNAs using RT-qPCR panels was performed in STEMI patients 
across 6 time points prior to and post-PPCI as well as in stable CAD controls to 
identify candidate endogenous miRNA controls (Figure 1A). The 4 most stable 
miRNAs identified in the screening phase were subsequently quantified in 34 STEMI 
patients to assess miRNA stability and validate a suitable miRNA endogenous 
control (validation phase – Figure 1B). The effects of heparin and bivalirudin 
administration on the three normalisation approaches (global miRNA mean, cel-miR-
39, and validated endogenous control) were also analysed as part of the validation 
phase (Figure 1B). Finally, the effect of the in vitro treatment of heparin-
contaminated samples with heparinase on cardiac-enriched miRNA (miR-1 and miR-
133b) quantification and its impact on the correlation between these miRNAs and 
high-sensitivity troponin T were evaluated in 70 STEMI patients (application phase - 
Figure 1C).      
2.2.  Plasma sample preparation and RNA isolation  
Blood samples were collected in EDTA-coated tubes (Becton Dickinson, USA) from 
a central arterial source up to 90 minutes post-PPCI using a 6F radial artery sheath 
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left in from the PPCI procedure for this purpose. The 120min, 180min, and 24h post-
PPCI samples from STEMI patients were collected from a peripheral venous source 
(antecubital vein). Immediately after collection, whole blood was centrifuged at 
1,500xg for 15 minutes at room temperature for plasma separation. Plasma samples 
were aliquoted and stored at -80°C until analysis. 
Following quick thaw of plasma samples at 37°C, total RNA was isolated from 200 
μL of plasma using the miRNeasy serum/plasma kit (Qiagen, Germany), according 
to the manufacturer’s protocol. Prior to addition of chloroform and aqueous phase 
separation, 3.5μL (1.6 x 108 copies/μL) of synthetic cel-miR-39 (Qiagen, Germany) 
were added to all samples. Assessment of total RNA concentration and integrity was 
performed by a 2100 Bioanalyzer instrument using the RNA 6000 Pico Kit (Agilent 
technologies, Germany) (Supplemental table 1). Additional details of the RNA 
extraction and concentration assessment procedures are included in the 
Supplemental methods.   
2.3.  miRNA quantification  
For miRNA screening, 4μL of total RNA were reverse transcribed using the Universal 
cDNA synthesis kit (Exiqon, Denmark). A total of 179 circulating miRNAs were 
quantified by RT-qPCR using serum/plasma focused miRNA PCR panels (Exiqon, 
Denmark) and the Exilent SYBR Green master mix (Exiqon, Denmark). To control for 
variations in efficiency at each experimental level, miRCURY LNA™ RNA spike-ins 
(Exiqon, Denmark) were equally added to the samples prior to RNA extraction (cel-
miR-39), cDNA synthesis (UniSp6), and PCR (UniSp3). Data quality control 
assessment was based on the quantification cycle (Cq) values obtained for these 
RNA templates across all samples (Supplemental figure 1). In addition, to minimize 
PCR inter-run variability, inter-plate calibration was performed according to the Cq 
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values obtained for UniSp3. The global miRNA expression mean was calculated as 
the geometric mean of Cq values obtained for all miRNAs, excluding miRNAs with 
Cq > 35. 
In the validation and application phases, 5μL of total RNA were reverse transcribed 
using the TaqMan® microRNA reverse transcription kit (Applied Biosystems, USA) 
and stem-loop specific TaqMan small RNA primers (Applied Biosystems, USA). 
Each miRNA was quantified using specific TaqMan microRNA assays (Applied 
Biosystems, USA) and the SensiFAST probe Hi-ROX master mix (Bioline, United 
Kingdom) in triplicates by a 7500 real-time PCR system (Applied Biosystems, USA). 
Calibration curves and efficiency of each assay and intra-assay variability are 
displayed in Supplemental figure 2 and Supplemental table 2, respectively.  
2.4. miRNA stability assessment 
To identify and validate the most stable endogenous miRNA, variability and stability 
assessments of candidate miRNAs were performed by calculation of the coefficient 
of variability (CV) and by the NormFinder v20 (15), geNorm v3.5 (16), and 
BestKeeper (17) software, respectively. These software applications utilize solid 
statistical algorithms to determine the variation in expression of multiple candidate 
normalisation genes across different samples. Lower stability scores in NormFinder 
(S score), geNorm (M score), and BestKeeper [standard deviation - std dev (±CP)] 
are expected for more stable miRNAs.  
2.5.  Heparin ELISA 
A solid-phase heparin enzyme-linked immunosorbent assay (ELISA) kit (BlueGene, 
China) containing wells pre-coated with monoclonal anti-porcine heparin antibody 
was used to confirm the presence and determine the concentration of heparin in both 
plasma (100μL) and RNA (10μL) samples from STEMI patients (n = 10). 
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Furthermore, the effect of RNA treatment with serial doses of heparinase I (Sigma-
Aldrich, USA) on heparin concentration in these samples was also assessed by 
ELISA. Different doses of heparinase I (0U, 0.25U, 0.5U, and 1U) were added to 
10μL of heparin-contaminated samples from the same STEMI patients (n = 3), 
incubated for 1 hour at room temperature. Heparin concentration was subsequently 
determined by ELISA. Detailed descriptions of the protocols for RNA treatment with 
heparinase and heparin ELISA are included in the Supplemental methods.  
2.6.  Effect of in vitro administration of heparin and bivalirudin on miRNA 
expression 
To assess the effect of in vitro heparin administration on miRNA detection by RT-
qPCR, serial doses of unfractionated heparin (Sigma-Aldrich, USA) were added to 
heparin-free RNA samples from STEMI patients (n = 3) and the difference in Cq 
values (ΔCq) to the heparin-free samples from the same STEMI patients were 
calculated after RT-qPCR. In addition, serial doses of heparinase I were added to 
heparin-contaminated RNA samples from STEMI patients (n = 3) to test whether and 
at which dose heparinase could reverse any potential effect of heparin on miRNA 
detection. Finally, to assess whether in vitro addition of bivalirudin (0.1 and 1 μg/μL - 
Sigma-Aldrich, USA) to RNA samples would have any effect on cel-miR-39 or the 
endogenous miRNA control expression, the ΔCq between bivalirudin-free and 
bivalirudin-treated RNA samples from the same patients with stable CAD (n = 3) 
were determined. Detailed information regarding the in vitro experiments with 
heparin and bivalirudin can be found in the Supplemental methods.  
2.7. Effect of in vivo administration of heparin and bivalirudin on miRNA 
expression 
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After identification of an adequate dose of heparinase that could rescue miRNA 
detection by RT-qPCR in heparin-contaminated samples (0.3U), the effect of in vivo 
heparin administration on miRNA expression was analysed by comparing the ΔCq 
between heparin-contaminated and heparinase-treated RNA samples from the same 
STEMI patients (n = 70).  To evaluate the effect of in vivo bivalirudin administration 
on the newly identified endogenous miRNA control, samples were obtained at 13 
successive time points from STEMI patients receiving either bivalirudin (n = 3) or 
heparin (n = 7). Aliquots from the heparin-contaminated RNA samples were treated 
with 0.3U of heparinase and miRNA expression was compared between heparin-
contaminated, heparinase-treated, and bivalirudin-contaminated samples.   
2.8.  Statistical analysis 
Statistical analysis was performed with SPSS software v22.0. Data normality was 
assessed using the Shapiro-Wilk test. Gaussian-distributed data were analysed 
using parametric tests (t test with Welch’s correction; paired t test; one-way ANOVA) 
and non-Gaussian data using non-parametric tests (Wilcoxon matched-pairs signed 
rank test). Correlations between variables were analysed with the Spearman’s 
correlation test. Data are presented as mean and standard error of the mean (SEM) 
or median and interquartile ranges (IQR) where appropriate and a p < 0.05 was 
considered statistically significant.     
3. Results 
 
3.1.  Study cohort 
Plasma samples were collected from a total of 73 STEMI patients undergoing PPCI. 
Optimal coronary perfusion (TIMI 3 flow) was obtained in 67 (93.1%) patients 
following PPCI. Clinical baseline characteristics of the study cohort are presented in 
Table 1. 
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3.2.  Identification and selection of candidate endogenous miRNA controls  
From the 179 quantified miRNAs, 60 presented Cq values < 35 across all 6 time 
points in STEMI patients and controls and were used for expression stability analysis 
by NormFinder and BestKeeper software (Supplemental figures 3A and 3B). The 
four most stable miRNAs identified by each algorithm were selected and an 
additional miRNA screening was performed in 6 STEMI patient samples to identify 
the four most stable miRNAs among this subgroup of eight miRNAs for further 
validation (miR-425-5p, miR-877-5p, miR-181a-5p, and miR-155-5p; Supplemental 
figure 3C).  
3.3.  miR-425-5p is a stably expressed endogenous miRNA in STEMI patients  
To validate the previously identified candidate endogenous miRNA controls, miRNA 
quantification was performed in samples from 34 STEMI patients collected at 24h 
post-PPCI, hence not contaminated with heparin. Amongst the 4 candidate miRNAs, 
miR-425-5p presented the best stability scores in NormFinder and BestKeeper and 
shared the best stability values in geNorm as well as the lowest CV with miR-181a-
5p (Table 2). In the entire STEMI cohort (n = 70), miR-425-5p expression was not 
influenced by age, sex, traditional cardiovascular risk factors, renal function, 
magnitude of myocardial damage (as reflected by cardiac troponin levels), or 
antiplatelet agents (glycoprotein IIb/IIIa inhibitors) administered during PPCI (Table 
1). In addition, miR-425-5p Cq values strongly and negatively correlated with total 
RNA concentration in patient samples (r = -0.744, p < 0.0001) but did not correlate 
with platelet count (r = 0.033, p = 0.786) or 12h cardiac troponin levels (r = -0.096, p 
= 0.429) (Supplemental figure 4). Therefore, miR-425-5p was selected as an 
endogenous control for RT-qPCR normalisation.   
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3.4. Heparin concentrations in RNA and plasma samples from STEMI patients 
are comparable and can be reduced by heparinase treatment of RNA 
samples  
Heparin was detected by ELISA in both plasma and plasma-derived RNA samples 
collected prior to myocardial reperfusion from the same STEMI patients (n = 10). 
Heparin concentration was similar between plasma [mean(±SEM) = 
1,387(±266)pg/mL] and RNA samples [1,113(±167.4)pg/mL], p = 0.247 (Figure 2A), 
suggesting significant heparin resistance to the process of RNA extraction from 
plasma. Treatment of heparin-contaminated RNA samples with 0.25U, 0.5U, and 1U 
of heparinase resulted in approximate reduction of 7% (±0.2%, p = 0.337), 30% 
(±0.1%, p = 0.001), and 42% (±0.1%, p < 0.001) in heparin concentration, 
respectively (Figure 2B), indicating a dose-dependent inhibitory effect of heparinase 
on heparin levels in RNA samples.  
3.5. Heparin inhibits the global miRNA mean, cel-miR-39, and miR-425-5p 
expression  
In STEMI patients receiving heparin (n = 3), global miRNA mean Cq values 
remained significantly elevated by 4 cycles immediately after heparin administration 
until 30min post myocardial reperfusion in comparison to 24h post-reperfusion levels 
(Figure 3A). In vitro treatment of the same RNA samples from these STEMI patients 
with heparinase I prior to reverse transcription reduced the global miRNA mean by 4 
cycles, bringing Cq values to similar levels of controls (Figure 3B).  
Similarly, in vitro addition of heparin to RNA samples from non-heparinised STEMI 
patients resulted in significantly increased cel-miR-39 and miR-425-5p Cq values in 
a dose-dependent fashion (Figures 3C and 3D). In fact, a heparin dose of 2U 
completely inhibited the detection of such miRNAs by RT-qPCR. In contrast, in vitro 
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treatment of heparin-contaminated RNA samples from STEMI patients with doses as 
low as 0.25U and 0.5U of heparinase I was effective in reducing Cq values of both 
cel-miR-39 (ΔCq = - 2.7, 95% CI: - 2.1 to - 3.3, p<0.0001) and miR-425-5p (ΔCq = - 
1.6, 95% CI: - 0.5 to - 2.7, p<0.01), respectively (Figures 3C and 3D).  
Furthermore, cel-miR-39 expression in heparin-contaminated RNA samples from 
STEMI patients (n = 35) was significantly inhibited by 1.5 cycles in comparison to 
non-heparinised samples from healthy and stable CAD controls (n = 12), which were 
spiked-in with the same number of cel-miR-39 copies (Figure 3E). Finally, in vivo 
administration of heparin to STEMI patients (n = 70) inhibited miR-425-5p expression 
by 2.4 cycles in comparison to heparinase-treated samples from the same patients 
(Figures 3F).  
3.6.  Bivalirudin does not affect cel-miR-39 or miR-425-5p expression 
Given heparin interference with all RT-qPCR normalisation approaches, the effect of 
bivalirudin, an anticoagulant that can be used alternatively during PPCI, on miR-425-
5p and cel-miR-39 expression was also investigated. In vitro addition of bivalirudin to 
RNA samples from control stable CAD patients did not affect miR-425-5p or cel-miR-
39 detection by RT-qPCR (Figure 4A). The effect of in vivo bivalirudin administration 
on miRNA expression in STEMI patients was assessed by comparing miR-425-5p 
expression between patients who received bivalirudin prior to PPCI and heparinase-
treated RNA samples from STEMI patients across 13 different time points prior to 
and after PPCI. No statistically significant difference in miR-425-5p expression was 
observed between these two groups at any time point (Figure 4B).    
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3.7.  Effect of RNA sample treatment with heparinase on cardiac-enriched 
miRNA expression  
To test whether the inhibitory effect of heparin on RT-qPCR normalisation strategies 
had any impact on cardiac-enriched miRNA quantification, miR-1 and miR-133b 
were quantified in heparinase-treated (0.3U) and heparin-contaminated samples 
collected at 30min post-PPCI from the same patients (n = 70) and RT-qPCR data 
normalised to miR-425-5p. Median miR-1 and miR-133b levels were 3-fold and 1.5-
fold higher in heparin-contaminated in comparison to heparinase-treated samples 
(p<0.0001), respectively (Figure 5A). This overestimation of cardiac-enriched 
miRNA levels in heparin-contaminated samples could partially be a result of the 
direct inhibition of heparin on the normalisation control (miR-425-5p) Cq values. 
Nonetheless, the different magnitudes of change in miR-1 and miR-133b expression 
after heparinase treatment suggested that heparin could also directly affect cardiac-
enriched miRNA detection in distinct degrees. Indeed, miR-133b expression was 
significantly reduced by in vitro treatment with low doses of heparin whereas 
treatment of heparin-contaminated RNA samples with heparinase was effective in 
improving miR-133b expression (Figure 5B). In contrast, higher, supra-physiological 
in vitro doses of heparin were required to significantly inhibit miR-1 expression and 
therefore heparinase treatment had no significant effect in restoring miR-1 Cq values 
in heparin-contaminated patient samples (Figure 5C).  
In addition, correlation of miR-1 and miR-133b with 12h post-PPCI, high-sensitivity 
cardiac troponin T was compared between heparinase-treated and heparin-
contaminated samples from the same STEMI patients. Treatment of RNA samples 
with heparinase improved the correlation between miR-1 and miR-133b levels at 30 
minutes post-PPCI and 12h Troponin T (miR-1: r = 0.602, p < 0.0001 vs. r = 0.510, p 
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< 0.0001; miR-133b: r = 0.540, p < 0.0001 vs. r = 0.520, p < 0.0001) (Figures 5D 
and 5E). Correlations between these cardiac-enriched miRNA levels at 90min post-
PPCI and troponin T were also evaluated in heparinase-treated samples (n = 70) 
and were slightly higher than those observed at 30min post-PPCI (miR-1: r = 0.692, 
p < 0.0001; miR-133b: r = 0.647, p < 0.0001). Expression of miR-1 and miR-133b 
were highly correlated, suggesting a common source for these miRNAs 
(Supplemental table 3).   
4. Discussion 
To the best of our knowledge, this is the first study to (i) identify and systematically 
validate a circulating miRNA as an endogenous control for RT-qPCR normalisation 
in STEMI patients; (ii) demonstrate that heparin administration simultaneously affects 
all currently proposed RT-qPCR normalisation strategies; (iii) show that bivalirudin 
does not affect the expression of exogenous or endogenous miRNA normalisation 
controls; (iv) validate the treatment of heparin-contaminated RNA samples with 
heparinase combined with RT-qPCR normalisation to miR-425-5p as a suitable 
approach for circulating miRNA quantification in a cohort of STEMI patients.  
The paucity of standardized procedures for circulating miRNA quantification, 
especially regarding RT-qPCR data normalisation, might explain discrepancies or 
reproducibility issues amongst circulating miRNA studies (18). Some studies in 
patients with acute myocardial infarction have used endogenous miRNAs, such as 
U6 snRNA (19-22), miR-16 (23), and miR-17 (24, 25), as normalisation controls. 
However, these miRNAs are not stably detected in the blood (U6 snRNA) (26), are 
susceptible to haemolysis (miR-16) (27), or were deemed stable based only on no 
statistical difference in expression between a small cohort of STEMI patients and 
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controls (miR-17) (24). Selection of a reference miRNA solely on the basis of no 
statistically significant difference in expression between groups is not sufficient to 
establish that the miRNA is a stable reference and should involve more detailed in 
silico analysis (10). Thus, an unequivocally stable circulating endogenous miRNA 
control remained to be validated.  
In this study, miR-425-5p was identified as a stably expressed miRNA using a robust 
statistical approach based on 3 established gene stability assessment software. In 
addition, miR-425-5p expression reflected RNA sample concentration, allowing this 
miRNA to correct for differences in the input RNA quantity amongst samples. This is 
highly valuable for circulating miRNA quantification considering that current miRNA 
reverse transcription protocols are based on same RNA input volume across 
different samples rather than same RNA concentration and that exogenous spike-in 
controls, although reflecting RNA extraction efficiency, are not able to correct for 
sources of variability such as input RNA quantity (10). Interestingly, miR-425-5p has 
also been validated as an endogenous control in patients with breast cancer (28). 
Circulating levels of miR-425-5p have otherwise been shown to be elevated in 
patients with colorectal (29) and cervical cancer (30) as well as in patients with 
traumatic brain injury (31), conditions that represented exclusion criteria for the 
present study. Data from miRNA tissue expression libraries (miRWalk 2.0, miRmine, 
miRGator 3.0) indicate high miR-425-5p expression in lymphoid cells, mammary 
glands, nasopharynx epithelium and mucosa, skin, brain, and testicular tissue (32-
34). In the context of STEMI, the cellular or tissue sources of miR-425-5p remain to 
be elucidated in future studies. Our data suggest that miR-425-5p is not significantly 
expressed in or released from the myocardium in STEMI patients as there was no 
correlation between this miRNA plasmatic expression and circulating levels of 
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cardiac troponin T. In contrast, strong correlations were observed between known 
cardiac-enriched miRNAs (miR-1 and miR-133b) and troponin T. In addition, data 
from validated miRNA tissue expression libraries showed irrelevant expression of 
miR-425-5p in the heart (32-34). Platelets have been previously shown to release 
their miRNA content, encapsulated in microparticles, following activation and 
aggregation in STEMI patients (35). In addition, it has been recently postulated that 
accurate miRNA quantification in stored plasma samples relies on efficient removal 
of residual platelets prior to cryopreservation, as freezing of plasma samples resulted 
in release of platelet-derived microparticles containing miRNAs, including miR-425-
5p, which expression strongly correlated with platelet count (36). However, in our 
study there was no correlation between miR-425-5p expression and baseline platelet 
count. Furthermore, miR-425-5p expression was not influenced by administration of 
antiplatelet aggregation medications (glycoprotein IIb/IIIa inhibitors) during PPCI in 
our cohort. 
In STEMI patients undergoing PPCI, intravenous heparin administration represents a 
major obstacle for miRNA quantification, given its known interference with essential 
components of qPCR reactions, such as DNA polymerases and magnesium ions, 
resulting in qPCR inhibition (37, 38). Here, we demonstrate that heparin affects all 
currently proposed RT-qPCR normalisation strategies, including the global miRNA 
mean expression. This finding contradicts the study by Kaudewitz et al. (12), which 
reported that normalisation to the average Cq value of quantified miRNAs was able 
to overcome heparin-related cel-miR-39 inhibition and consequent overestimation of 
circulating miRNA levels in patients with acute coronary syndrome (ACS). In that 
study, however, miRNA mean expression was calculated based on the Cq values of 
only 14 miRNAs, some of which are known to be deregulated in patients with ACS. 
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In accordance with our findings, inhibition of cel-miR-39 detection within the initial 
hour of heparin administration has been previously reported in smaller cohorts of 
patients undergoing coronary angiography (11, 12).  
On top of its general inhibition over PCR reactions, a selective inhibitory effect of 
heparin on endogenous circulating cardiovascular-related miRNAs detection by RT-
qPCR has been reported by Boeckel et al. (11). In that study, miR-1, miR-92a, miR-
126, miR-17, and miR-145 expression was not significantly altered after heparin 
administration to patients undergoing cardiac catheterisation (n = 11), whereas miR-
133a, miR-34a, miR-378, and miR-499 detection was significantly reduced. No 
interference in miRNA detection was observed after addition of recombinant miR-92a 
and miR-126 to heparin-contaminated plasma samples as opposed to significant 
inhibition following addition of recombinant cel-miR-39 to the same samples, further 
suggesting an inhibitory effect of heparin towards specific miRNAs (11). Similarly, in 
our study, higher in vitro doses of heparin were required to inhibit miR-1 expression 
in non-heparinised STEMI samples when compared to miR-133b and miR-425-5p. 
This might explain why in vitro RNA treatment with heparinase was not effective in 
restoring miR-1 detection in heparin-contaminated samples from STEMI patients, in 
which heparin concentrations are lower than those necessary to inhibit miR-1 
expression in our in vitro experiments. Consequently, following heparinase treatment 
of heparin-contaminated RNA samples from STEMI patients and PCR data 
normalisation to miR-425-5p, we observed different magnitudes of change in miR-1 
and miR-133b expressions. A more pronounced reduction in miR-1 expression (3-
fold) probably reflects the isolated effect of heparinase treatment in improving the 
endogenous normalisation control detection whereas the discreet reduction in miR-
133b expression (1.5 fold) might result from a synergistic improving effect of 
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heparinase treatment on both the normaliser (miR-425-5p) and miR-133b detection. 
The mechanism behind this selective effect of heparin on miRNA detection is 
unknown. Future studies should investigate whether and how heparin interacts with 
the chemical structure of different miRNAs or plasmatic miRNA-binding proteins, 
such as Argonaute proteins (39).          
Previous studies have also demonstrated that treatment of cellular and circulating 
RNA samples with heparinase could overcome heparin-induced RT-qPCR inhibition 
(40, 41). Whilst this manuscript was under preparation, Li S et al. (13) reported that 
heparinase treatment of RNA samples could abrogate heparin-induced impaired 
detection of cel-miR-39 in patients with CAD undergoing coronary intervention.  Our 
data not only corroborate these findings but also show that treatment of heparin-
contaminated RNA samples with heparinase improves the global miRNA mean and 
endogenous miRNA control (miR-425-5p) detection by RT-qPCR in STEMI patients 
post-PCI.  
In this study, we also sought to explore whether bivalirudin had any effect on the 
expression of endogenous and exogenous miRNA normalisation controls. Bivalirudin 
is an anti-thrombotic medication that can be used for anticoagulation therapy during 
PCI in STEMI patients, especially in those with heparin-induced thrombocytopenia 
(42). In vitro and in vivo bivalirudin administration did not interfere with miR-425-5p 
or cel-miR-39 expression. This suggests that RNA samples obtained from patients 
treated with bivalirudin could be an alternative to circumvent heparin interference 
with RT-qPCR normalisation for clinical studies of circulating miRNAs in STEMI 
patients.  
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In addition, we observed that RNA treatment with heparinase improved the 
correlation of cardiac-enriched miRNAs post-reperfusion levels with high-sensitivity 
troponin T. Although elevated cardiac-enriched miRNA levels have been shown in 
STEMI patients, it remains controversial whether they correlate with the extent of 
cardiac injury (19, 43, 44). Data from the very few studies that performed serial 
cardiac-enriched miRNA quantification post-PPCI suggest that peak levels of these 
miRNAs occur in the initial 3-4h post-PPCI and correlated with markers of 
cardiomyocyte necrosis (20, 24, 45). Because this time window coincides with that of 
heparin’s plasmatic half-life, our results allow future studies to overcome RT-qPCR 
inhibition and normalisation issues to carry out more detailed kinetics analysis in the 
initial hours post-PPCI and investigate whether cardiac-enriched miRNA levels after 
reperfusion reflect myocardial damage assessed by cardiac imaging.  
This study presents some limitations. High throughput qPCR panels were used 
instead of microarray or RNA sequencing approaches for miRNA profiling and 
therefore could not identify novel miRNAs to be tested as stable endogenous 
controls. Furthermore, we did not evaluate whether miR-181a-5p, the second most 
stable endogenous miRNA, could produce similar results to miR-425-5p in terms of 
cardiac-enriched miRNA normalisation either separately or in association with miR-
425-5p. Finally, we could not demonstrate a significant reduction in heparin 
concentration in RNA samples treated with 0.25U of heparinase by ELISA, whilst this 
dose was effective in restoring miRNA detection by RT-qPCR. We hypothesise that, 
due to RT-qPCR very high sensitivity, miRNA detection by RT-qPCR can be 
influenced by even small variations in heparin concentration in RNA samples, which 
ELISA might not be sensitive enough to detect.    
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In conclusion, this study addressed important methodological hurdles to accurate 
quantification of circulating miRNAs in STEMI patients. Our results have also 
implications for circulating miRNA studies in other cohorts to which anticoagulation 
therapy is administered, e.g. patients undergoing organ transplantation or heart 
surgery. In addition, we reinforce the evidence that levels of cardiac-enriched 
miRNAs early after myocardial reperfusion reflect the severity of cardiac injury. 
Finally, we suggest that the use of samples from bivalirudin-treated patients or in 
vitro treatment of heparin-contaminated samples with heparinase, associated with 
normalisation to miR-425-5p, are suitable strategies for miRNA quantification in 
STEMI patients, thus providing new tools to reduce variability and allow future 
detailed kinetics studies of circulating miRNAs in this population. 
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Figure legends  
 
Figure 1. Study design. The study was carried out in three consecutive phases. In 
the screening phase (A), a total of 179 microRNAs were initially quantified in 
samples from 3 STEMI patients and 4 control samples using real time quantitative 
reverse transcription (RT-qPCR) panels to identify 8 candidate endogenous miRNA 
controls. In a second step of this phase, miRNA screening was performed in 
samples collected at 30min post-PCI from 6 STEMI patients and subsequently 
treated in vitro with heparinase to select the 4 most stable candidate endogenous 
miRNAs and to assess the effect of heparin and heparinase administration on the 
global miRNA mean expression (B), the 4 candidate miRNAs previously identified 
were quantified by TaqMan RT-qPCR in 34 STEMI samples collected 24h post-PCI 
(heparin-free) and miRNA stability was determined. In addition, cel-miR-39 and the 
validated endogenous miRNA control were quantified in a total of 70 STEMI samples 
collected at 30min post-PCI (cel-miR-39, n = 35; endogenous miRNA control, n = 70) 
to evaluate the effect of in vivo administration of heparin on these miRNA controls 
expression. To further assess the in vivo effect of bivalirudin on the exogenous 
spike-in and endogenous miRNA controls, these miRNAs were quantified in samples 
collected from STEMI patients (n = 3) at 13 time points prior to and following PCI. 
Finally, in the application phase (C), heparin-contaminated RNA samples from the 
same 70 STEMI patients (30min post-PCI) were treated in vitro with heparinase and 
cardiac-enriched miRNAs (miR-1 and miR-133b) were quantified to assess the 
impact of heparin contamination and heparinase treatment on the levels of such 
miRNAs. Furthermore, correlation of cardiac-enriched miRNA levels with 12h post-
PPCI Troponin T was also analysed.  
 
Figure 2. In vitro treatment with heparinase decreases heparin concentration in 
RNA samples from STEMI patients. Heparin was quantified in plasma and plasma-
derived RNA samples collected prior to myocardial reperfusion from STEMI patients 
by ELISA. (A) Presence of heparin was confirmed in both plasma and RNA samples. 
Heparin concentration was similar between plasma [mean(±SEM) = 
1,387(±266)pg/mL] and RNA samples [1,113(±167.4)pg/mL], p = 0.247; n = 10; ns, 
non-significant; paired t test. (B) Serial doses of heparinase I (0.25U, 0.5U, and 1U) 
were added to heparin contaminated samples from STEMI patients (n = 3), 
incubated for 1 hour at room temperature, and heparin concentration was 
subsequently assessed by ELISA. Addition of 0.5U and 1U were effective in 
reducing heparin concentration by approximately 30% and 42%, respectively, in 
relation to heparin-contaminated samples not treated with heparinase; **p=0.001 
***p<0.001 vs. control samples, one-way ANOVA and Dunnett’s multiple comparison 
test.     
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Figure 3. Heparin inhibitory effect on the global miRNA mean, cel-miR-39, and 
miR-425-5p expression. (A) STEMI patients treated with heparin displayed 
significantly higher global miRNA mean Cq across the initial 30min following 
myocardial reperfusion in comparison to 24h values, when heparin was not present 
in the circulation; n = 3; ns, non-significant, ****p<0.0001 vs 24h; Repeated-
measures one-way ANOVA and Dunnett’s multiple comparison test; (B) To confirm 
in vitro whether heparin inhibits the global miRNA mean expression, heparin-
contaminated RNA samples were treated with 0.3U of heparinase prior to reverse 
transcription and the difference in the global miRNA mean between these samples 
and non-heparinised, stable CAD controls (ΔCq) was calculated. Heparin-
contaminated samples not treated with heparinase presented global miRNA mean 4 
cycles higher than controls whereas samples from the same patients that were 
treated with heparinase had similar miRNA mean Cq to controls; n = 3; ns, non-
significant, ****p<0.0001 vs stable CAD controls; one-way ANOVA and Dunnett’s 
multiple comparison test; (C, D) Effect of in vitro addition of serial doses of heparin or 
heparinase to RNA samples on cel-miR-39 and miR-425-5p expression. Seven 
different doses of heparin were added to RNA samples from STEMI patients not 
treated with heparin and changes on cel-miR-39 and miR-425-5p Cq were compared 
to the control, heparin-free samples (ΔCq). Heparin significantly inhibited both cel-
miR-39 and miR-425-5p expression, whereas 2U completely inhibited miRNA 
detection by RT-qPCR. In contrast, treatment of heparin-contaminated samples from 
STEMI patients with 5 different doses of heparinase reduced Cq values, n = 3; ns, 
non-significant, *p<0.05, **p<0.01, ****p<0.0001; one-way ANOVA and Dunnett’s 
multiple comparison test; (E, F) In vivo effect of heparin administration on cel-miR-39 
and miR-425-5p expression. Cel-miR-39 expression was significantly inhibited in 
heparin-contaminated STEMI samples (n = 35) in comparison to non-heparinised 
samples from healthy and stable CAD controls (n = 12), which were spiked-in with 
the same number of cel-miR-39 copies ***p<0.001, Mann-Whitney U test. Similarly, 
miR-425-5p expression was inhibited by 2.4 cycles in heparin-contaminated versus 
heparinase-treated RNA samples from the same patients, n = 70; ****p<0.0001, 
Wilcoxon matched-pairs signed rank test. 
 
Figure 4. Bivalirudin does not affect miR-425-5p or cel-miR-39 expression. (A) 
In vitro addition of bivalirudin to RNA samples from patients with stable coronary 
artery disease did not result in changes on miR-425-5p or cel-miR-39 Cq values, n = 
3; ns, non-significant, one-way ANOVA and Dunnett’s multiple comparison test; (B) 
To evaluate the effect of bivalirudin on miR-425-5p in vivo, samples were obtained at 
13 different time points from STEMI patients receiving either bivalirudin (n = 3) or 
heparin (n = 7). Aliquots from the heparin-contaminated RNA samples were treated 
with 0.3U of heparinase and miR-425-5p expression was compared between 
heparin-contaminated, heparinase-treated, and bivalirudin-contaminated samples. 
Significantly reduced Cq values were observed in heparinase-treated samples in 
comparison to heparin-contaminated samples from the same patients up to 30min 
post-PCI; *p<0.05, Wilcoxon matched-pairs signed rank test. No statistically 
significant differences were observed in miR-425-5p expression between 
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heparinase-treated and bivalirudin-contaminated samples; ns, non-significant, Mann-
Whitney U test.  
 
Figure 5. Effect of RNA sample treatment with heparinase on cardiac-enriched 
miRNA expression. (A) To assess whether RNA treatment with heparinase could 
affect cardiac-enriched miRNA quantification, miR-1 and miR-133b were quantified 
in heparinase-treated (0.3U) and heparin-contaminated samples collected at 30min 
post-PPCI from the same patients and data normalised to miR-425-5p. Expression of 
miR-1 and miR-133b in heparinase-treated sampled were 3-fold and 1.5-fold lower 
than that of heparin-contaminated samples; n = 70, ****p<0.0001; Wilcoxon 
matched-pairs signed rank test; (B, C) Effect of in vitro addition of serial doses of 
heparin or heparinase to RNA samples on miR-133b and miR-1 expression. 
Expression of miR-133b was affected by almost all tested doses of heparin and 
heparinase. In contrast, miR-1 Cq values were only affected by higher, supra-
physiological doses of heparin and not significantly affected by heparinase in 
heparin-contaminated patient samples, n = 3; ns, non-significant, *p<0.05, **p<0.01, 
****p<0.0001 vs controls; one-way ANOVA and Dunnett’s multiple comparison test; 
(D, E) Effect of heparinase treatment on the correlation of cardiac-enriched miRNAs, 
miR-1 and miR-133b, with 12h post-PPCI troponin T, n = 70.   
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Extra table 
 
What is known in this topic 
• Lack of consensus regarding RT-qPCR normalisation for miRNA quantification in 
STEMI patients contributes to irreproducibility amongst studies and impairs 
translation of miRNAs to clinical practice 
• There is no validated endogenous miRNA normalisation control in STEMI patients 
• Heparin inhibits the detection of the commonly used exogenous miRNA 
normalisation control cel-miR-39 
What this paper adds 
• We identified and validated miR-425-5p as a stable endogenous miRNA control in 
STEMI patients 
• Besides its effect on cel-miR-39, heparin also interferes with the other two currently 
proposed RT-qPCR normalisation strategies for miRNA quantification (i.e. global 
miRNA mean and miRNA endogenous control) 
• RNA samples from bivalirudin-treated STEMI patients or in vitro treatment of heparin-
contaminated samples with heparinase can be used to circumvent heparin-related 
issues in RT-qPCR inhibition and normalisation 
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Table 1. Clinical characteristics of the study population 
Variable 
Entire 
cohort 
Endogenous miR control Cq values* p 
value 1st tertile 2nd tertile 3rd tertile 
Number (male) 73 (61)  24 (20) 25 (20) 24 (21) 0.898 
Age [years, median  
(IQR)] 
63  
(55 – 71) 
65 
(56 – 71) 
65 
(59 – 70) 
61 
(52 – 71) 
0.396 
Risk factors, n (%)      
Smoking status      
Never smoked 28 (38.9) 10 (41.7) 7 (29.2) 11 (45.8) 0.468 
Ex-smoker 24 (33.3) 9 (37.5) 11 (45.8) 4 (16.7) 0.087 
Current smoker 20 (27.8) 5 (20.8) 6 (25) 9 (37.5) 0.407 
Hypertension 17 (23.6) 4 (16.7) 7 (29.2) 6 (25) 0.583 
Diabetes mellitus 6 (8.3) 3 (12.5) 3 (12.5) 0 (0) 0.195 
Hypercholesterolaemia 7 (9.7) 3 (12.5) 2 (8.3) 2 (8.3) 0.854 
Obesity 25 (34.7) 8 (33.3) 13 (56.5) 4 (16.7) 0.230 
Malignancies 0 (0) 0 (0) 0 (0) 0 (0) - 
Laboratory tests  
[median (IQR)] 
 
    
Admission eGFR, mL/min 83 (73 – 97) 
 
82 (68 – 92) 83 (75 – 112) 83 (69 – 93) 0.441 
Admission Troponin T,  
ng/L 
49 
(27 – 98) 
33 
(27 – 72) 
61 
(28 – 184) 
46 
(25 – 141) 
0.346 
Peak Troponin T, ng/L 3255 
(1109 – 5658) 
3422 
(1712 – 6441) 
2262 
(745 – 6367) 
3119 
(1179 – 5152) 
0.533 
STEMI characteristics      
Onset to reperfusion (min) 157 
(110 – 245) 
144 
(102 – 216) 
225 
(124 – 295) 
147  
(112 – 248) 
0.156 
Culprit vessel, n (%)      
LAD 22 (30.6) 6 (25) 10 (41.7) 6 (25) 0.351 
LCx 13 (18) 5 (20.8) 3 (12.5) 5 (20.8) 0.687 
RCA 37 (51.4) 13 (54.2) 11 (45.8) 13 (54.2) 0.801 
Localization, n (%)       
Anterior 22 (30.6) 6 (25) 10 (41.7) 6 (25) 0.351 
Non-anterior 50 (69.4) 18 (75) 14 (58.3) 18 (75) 0.351 
TIMI flow pre PPCI, n (%)       
0 60 (83.3) 21 (87.5) 19 (79.2) 20 (83.3) 0.741 
1 10 (13.9) 3 (12.5) 4 (16.7) 3 (12.5) 0.890 
2  1 (1.4) 0 (0) 0 (0) 1 (4.2) 0.363 
3 1 (1.4) 0 (0) 1 (4.2) 0 (0) 0.363 
TIMI flow post PPCI, n (%)      
0 1 (1.4) 0 (0) 1 (4.2) 0 (0) 0.363 
1 3 (4.2) 0 (0) 1 (4.2) 2 (8.3) 0.352 
2 1 (1.4) 0 (0) 0 (0) 1 (4.2) 0.363 
3 67 (93.1) 24 (100) 22 (91.7) 21 (87.5) 0.222 
Medication during PPCI      
Heparin, n (%) 70 (95.8) 24 (100) 24 (96) 22 (91.7) 0.328 
Bivalirudin, n (%) 3 (4.2) 0 (0) 1 (4) 2 (8.3) 0.328 
Glycoprotein IIb/IIIa 
inhibitors, n (%) 
48 (66.7) 15 (62.5) 18 (75) 15 (62.5) 0.570 
eGFR, estimated glomerular filtration rate; LAD, left anterior descending; LCx, left circumflex; PPCI, 
primary percutaneous coronary intervention; RCA, right coronary artery; TIMI, thrombolysis in 
myocardial infarction; * endogenous miRNA control Cq values at 30 minutes post myocardial 
reperfusion (expression quantified in heparinase-treated RNA samples, except in samples from 
bivalirudin-treated patients) 
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Table 2.  Candidate endogenous miRNA controls expression stability  
microRNA 
geNorm 
M score 
Normfinder 
S score 
Bestkeeper 
Std dev (±CP)   
CV (%) 
miR-425-5p 1.13 1.85 1.47 7 
miR-181a-5p 1.13 2.09 1.51 7 
miR-155-5p 2.62 2.04 4.03 14 
miR-877-5p 2.72 2.18 3.97 13 
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Figure 5 
SUPPLEMENTS 
 
1. Supplemental methods 
 
1.1. RNA extraction  
RNA was isolated from 200μL of plasma samples, which had been cryopreserved at 
-80°C for 6 months to 1 year prior to analysis (Freeze/thaw cycles = 2 to all 
samples). The miRNeasy serum/plasma kit (Qiagen, Germany) was used for RNA 
extraction, following the manufacturer’s instructions. Fixed volumes of each of the 
kit’s reagents used throughout the entire study were as follows:  
Plasma sample  ………………..  200μL 
Qiazol reagent   …………....... 1,000μL 
Cel-miR-39 spike-in  …………… 3.5μL 
 Chloroform   …………...............  200μL 
 Aqueous phase   …………........ 500μL 
 100% Ethanol   …………........... 750μL 
  RWT buffer   ……………........... 700μL 
  RPE buffer   ……………............ 500μL 
  80% Ethanol   ….………............ 500μL 
                                 RNAse free water  
                                 (for final RNA elution)….…......... 60μL 
 
Following RNA extraction, quantification of total RNA in each sample was performed 
using RNA 6000 Pico Kit (Agilent technologies, Germany) by a 2100 Bioanalyzer 
instrument (Supplemental table 1). RNA integrity was assessed by the RNA 
integrity number (RIN).  Quality assessment in RNA samples obtained from plasma 
is challenging because of the very low yield of RNA in these samples and therefore 
RIN must be interpreted with caution, as recommended by the MIQE guidelines.  
 2 
1.2. Heparin ELISA 
 
Heparin was quantified in plasma and RNA samples using a competitive enzyme-
linked immunosorbent assay (ELISA) kit (BlueGene, China), containing wells pre-
coated with monoclonal anti-porcine heparin antibody. Plasma (100μL) and RNA 
(10μL; diluted in 90μL of PBS to a final volume of 100μL) samples were incubated 
with a heparin-horseradish peroxidase (HRP) conjugate in the pre-coated wells at 
37°C for 1 hour. PBS only (100μL) was added to blank control wells and appropriate 
standards (100μL) containing six serial concentrations of heparin (range: 0pg/mL – 
2,500pg/mL) were included in duplicates to generate a standard curve for heparin 
concentration calculation in STEMI samples. After the incubation period, the sample-
conjugate solution was removed and wells were washed 6 times with 200μL of 
washing buffer. A substrate for HRP (100μL) was then added to each well and 
incubated at 37°C for 15 minutes, including the blank wells. Finally, a stop solution 
was added to the wells and absorbance was immediately measured at 450nm 
wavelength by spectrophotometry (Varioskan lux, Thermo Fisher Scientific, USA). A 
standard curve (below) was generated using a four-parameter logistic (4-PL) curve-
fit. Heparin concentration in the samples was calculated based on the standard 
curve and dilution factor (RNA samples) by the SkanIt software (Thermo Fisher 
Scientific, USA).  
 
y = 1.73465 + ((0.135615 - 1.73465) 
/ (1 + (x/858.255)^-1.1809)) 
 
R² =  0.967 
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To test the effect of RNA sample treatment with heparinase on heparin 
concentration, 10μL of heparin-contaminated RNA samples from the same patients 
(n = 3) were incubated with different doses of heparinase (0U, 0.25U, 0.5U, and 1U) 
at room temperature for 1 hour prior to ELISA.  
 
1.3. Reverse transcription  
 
In the screening phase, RNA was reverse transcribed using the Universal cDNA 
synthesis kit II (Exiqon, Denmark), by mixing RNA samples with kit components 
followed by incubation in thermocyler according to the manufacturer’s protocol, as 
indicated below: 
RT reaction components Volume (μL/per reaction) 
RNA sample 4 
5X Reaction buffer 4 
Enzyme mix 2 
UniSp6 spike-in 1 
Nuclease free water 9 
Total reaction volume 20 
 
Thermocycler settings for RT reaction 
 Incubation  ……………... 42°C….. 60min 
 Heat/Inactivation  ….…... 95°C…... 5min 
 
In the validation and application phases, cDNA was synthesized using the TaqMan® 
microRNA reverse transcription kit (Applied Biosystems, USA) and stem-loop 
TaqMan miRNA primers (Applied Biosystems, USA), as follows:  
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RT reaction components Volume (μL/per reaction) 
RNA sample 5 
dNTPs 0.15 
Reverse transcriptase 1 
10X RT buffer 1.5 
RNAse inhibitor 0.19 
Nuclease free water 4.16 
TaqMan 5X miRNA assay 3 
Total reaction volume 15 
 
 
Thermocycler settings for RT reaction 
 Incubation  ……………... 16°C….. 30min 
 Incubation  ……………... 42°C….. 30min 
 Heat/Inactivation  ….…... 85°C…… 5min 
For each assay, a control containing all reagents apart from reverse transcriptase 
was included to assess the presence of DNA contamination.  
 
1.4. Real-time qPCR 
 
Only fresh cDNA samples were used for real-time qPCR amplification. In the 
screening phase, a panel of 179 miRNAs were quantified using serum/plasma 
focused miRNA PCR panels (Exiqon, Denmark) containing different primers for the 
target miRNAs in each well. Volumes of reaction components and qPCR conditions 
are described below: 
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qPCR reaction components Volume (μL/per plate) 
cDNA sample 10 
Exilent SYBR Green master 
mix    
500 
Nuclease free water 490 
Total volume per plate 1000 
Total volume per well 10 
 
7500AB instrument settings for qPCR reaction 
 Polymerase activation/denaturation…... 95°C….. 10min 
 Denaturation (40 cycles)  .……………... 95°C….. 10sec 
 Annealing/extension (40 cycles) .…...... 60°C….. 60sec 
                          Melting curve analysis 
 
In the validation and application phases, TaqMan small RNA assays and the 
SensiFAST probe Hi-ROX master mix (Bioline, UK) were used for qPCR in 
triplicates:  
 
qPCR reaction components Volume (μL/per triplicates) 
cDNA sample 4.8 
TaqMan small RNA assay 
(20X) 
3.6 
SensiFAST probe Hi-ROX 
master mix 
36 
Nuclease free water 27.6 
Total volume  72 
Total volume per well 20 
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7500AB instrument settings for qPCR reaction 
 Polymerase activation/denaturation…... 95°C….. 10min 
 Denaturation (40 cycles)  .……………... 95°C….. 15sec 
 Annealing/extension (40 cycles) .…...... 60°C….. 60sec 
 
For each of the 9 TaqMan small RNA assays used in this study, calibration curves 
based on cDNA serial dilutions (Dilution factor = 4) were produced for the 
assessment of primer efficiency and qPCR linear dynamic range. Primer efficiency 
(E%) was calculated as a function of the calibration curves slopes; E = 10(-1/slope). All 
assays presented E% between 95% and 105% as well as coefficient of 
determination (R2) > 0.98, indicating optimal qPCR amplification (Supplemental 
figure 2). In addition, intra-assay variability across biological replicates was also 
determined for all miRNA assays (Supplemental table 2). Finally, two types of non-
template controls were included for each assay: (i) no reverse transcriptase controls, 
as mentioned above, to evaluate genomic DNA contamination; (ii) controls in which 
cDNA template was replaced by nuclease free water, to assess background noise. 
These controls displayed undetected Cq values in all plates.  
The comparative Cq (ΔΔCq) method was used to determine Cq values and real-time 
qPCR data was analyzed using the 7500 software v2.0.5. Fold changes were 
calculated using the 2-ΔΔCq method.  
1.5. In vitro experiments with heparin, heparinase, and bivalirudin  
To evaluate whether the in vitro addition of heparin to heparin-free RNA samples 
from STEMI patients could affect miRNA detection, serial doses of heparin sodium 
(1,000 I.U/mL; Sigma-Aldrich) were added to 5μL aliquots from the same RNA 
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patient samples (n = 3) and the reverse transcription reaction components prior to 
reverse transcription according to the following scheme:  
Sample 
Heparin 
concentration 
(U) 
Control 
(Heparin-free) 
0 
1 2 
2 1 
3 0.5 
4 0.25 
5 0.1 
6 0.05 
7 0.005 
 
RT reaction components Volume (μL/per reaction) 
RNA sample 5 
Heparin 1 
dNTPs 0.15 
Reverse transcriptase 1 
10X RT buffer 1.5 
RNAse inhibitor 0.19 
Nuclease free water 3.16 
TaqMan 5X miRNA assay 3 
Total reaction volume 15 
 
 
To test whether RNA sample treatment with heparinase could abrogate heparin 
effects and identify an appropriate dose, aliquots from the same heparin-
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contaminated RNA samples from STEMI patients (n = 3) were incubated with serial 
doses of heparinase I from Flavobacterium heparinum (Sigma-Aldrich), 10x reverse 
transcription buffer, and RNAse inhibitor for 1 hour at room temperature, as 
previously described by Johnson ML et al. (1) and Li S et al.(2): 
 
Sample 
Heparinase 
concentration (U) 
Control 
(heparin-contaminated) 
0 
1 1 
2 0.25 
3 0.5 
4 0.1 
 
RT reaction components 
(Part 1: incubation with heparinase) 
Volume (μL/per reaction) 
RNA sample 5 
Heparinase 1 
10X RT buffer 1.5 
RNAse inhibitor 0.19 
 
 
After incubation, the remaining components of the reverse transcription reaction 
were added in the same volumes as described above for the heparin spike-in 
experiment and reverse transcription was performed:  
RT reaction components 
(Part 2) 
Volume (μL/per reaction) 
dNTPs 0.15 
Reverse transcriptase 1 
Nuclease free water 3.16 
TaqMan 5X miRNA assay 3 
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For the bivalirudin spike-in experiment, 1μL of bivalirudin (Sigma-Aldrich) at the 
concentrations of 0.1 and 1μg/μL were added to aliquots of the same RNA samples 
from stable coronary artery disease patients (n = 3) prior to reverse transcription as 
follows:  
 
RT reaction components Volume (μL/per reaction) 
RNA sample 5 
Heparin 1 
dNTPs 0.15 
Reverse transcriptase 1 
10X RT buffer 1.5 
RNAse inhibitor 0.19 
Nuclease free water 3.16 
TaqMan 5X miRNA assay 3 
Total reaction volume 15 
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Supplemental figure 1. MicroRNA screening data quality control. Three synthetic 
microRNA spike-ins were equally added to all samples included in the screening phase to 
assess the efficiency of each experimental step: RNA extraction (cel-miR-39), cDNA 
synthesis (UniSp6), and qPCR (UniSp3). Expression of cel-miR-39 was significantly lower 
up to 5 minutes post-reperfusion, with a trend of higher Cq values up to 30 minutes, in 
comparison to non-heparinised stable coronary artery disease (CAD) control samples (A), 
most likely reflecting reduced cel-miR-39 qPCR detection as a result of heparin inhibition 
rather than true differences in RNA extraction efficiency between samples. Data 
expressed as median and interquartile range; *p<0.05; Kruskal-Wallis test with Dunn’s 
correction for multiple comparisons. (B) Expression of UniSp6 was also significantly 
decreased up to 5 minutes post-reperfusion in STEMI patients receiving heparin in 
comparison to controls. Data expressed as median and interquartile range; *p<0.05; 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons. (C) UniSp3 detection 
was very stable amongst all samples, indicating similar qPCR efficiency. UniSp3 Cq 
values were used as a normalizer for inter-plate calibration to minimize inter-run 
variability.  
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Supplemental figure 2. Taqman small RNA assay calibration curves. Serial cDNA template 
dilutions (dilution factor = 4) were performed and calibration curves were plotted. The coefficient 
of determination (R2) and slope for each curve are displayed. Primer efficiency (E%) was 
calculated as a function of the slope, E = 10(-1/slope). Quantification cycle (Cq) values are displayed 
as the average of 3 technical replicates.  
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2. Supplemental Results 
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Supplemental Figure 3. Selection of candidate endogenous miRNA controls 
following screening. After miRNA screening in 3 STEMI patients and 4 controls, 
60 miRNAs presented Cq values < 35 across all time points and had their stability 
determined by NormFinder and BestKeeper. The four most stable miRNAs below 
the M score threshold of 0.5 identified by NormFinder (A) and the four most stable 
miRNAs with standard deviation < 1 in BestKeeper (B) were selected for further 
validation. Note that cel-miR-39 is amongst the least stable miRNAs in both 
algorithms. (C) Following screening of 179 circulating miRNAs in 6 samples 
collected from STEMI patients 30min post percutaneous coronary intervention 
(PCI), which were treated in vitro with 0.3U of heparinase, and 4 controls with 
stable coronary artery disease (CAD), the 4 most stably expressed endogenous 
miRNAs (miR-425-5p, miR-877-5p, miR-181a-5p, miR-155-5p - highlighted) were 
identified by NormFinder. The lower the stability (S) value in NormFinder the more 
stable the reference miRNA. These miRNAs were selected for further validation 
by TaqMan RT-qPCR assays in a larger cohort of STEMI patients.   
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Supplemental Figure 4. Correlation of miR-425-5p with sample RNA concentration 
and platelet count. (A) miR-425-5p expression strongly and negatively correlated with 
total RNA concentration in STEMI patient samples, n = 70. (B) miR-425-5p expression at 
30min post-PPCI did not correlate with admission platelet count, n = 70. (C) miR-425-5p 
expression at 30min post-PPCI did not correlate with peak cardiac troponin T, n = 70. 
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Supplemental table 1. Total RNA concentration and integrity assessment 
Sample 
Agilent 2100 
Bioanalyzer 
  Sample 
Agilent 2100 
Bioanalyzer 
RNA conc. 
(pg/μL) 
   RIN 
RNA conc. 
(pg/μL) 
RIN 
ID001 30min 1062.9 2.7 ID146 90min 1020.7 2.8 
ID001 90min 604.3 2.5 ID147 30min 199.7  2.5 
ID002 30min 571.4 3 ID147 90min 350.6  2.7 
ID002 90min 1065.9 3.2 ID148 30min 357.2 2.6 
ID003 30min 3217.5 3.9 ID148 90min 743 2.8 
ID003 90min 3660.7 4.5 ID149 30min 153.1 2.5 
ID004 30min 2249.2 3.3 ID149 90min 195.8 2.5 
ID004 90min 3719.9 3.4 ID150 30min 758.4 2.6 
ID005 30min 362.5 2.5 ID150 90min 616.6  2.7 
ID005 90min 611.2 2.7 ID152 30min 523.9 3 
ID006 30min 341.3 2.6 ID152 90min 1666 2.6 
ID006 90min 552.3 3 ID153 30min 710.9 2.7 
ID007 30min 280 2.4 ID153 90min 346.5 2.7 
ID007 90min 389.5 3 ID154 30min 173 2.8 
ID008 30min 309.2 2.3 ID154 90min 657 2.9 
ID008 90min 309.7 2.7 ID206 30min 2230.6 3.5 
ID009 30min 395.9 2.7 ID206 90min 2898.3 4.6 
ID009 90min 513.5 2.9 ID207 30min 213 2.5 
ID010 30min 100.6 2.5 ID207 90min 407.1 2.7 
ID010 90min 320.2 2.5 ID501 30min 338.2 3.4 
ID012 30min 900.7 3.3 ID501 90min 292 3 
ID012 90min 613.9 3.1 ID570 30min 581.8 2.6 
ID069 30min 203 2.8 ID570 90min 453.6 2.8 
ID069 90min 1113.5 3 ID571 30min 569.2 2.5 
ID138 30min 428 2.6 ID571 90min 392.7 2.5 
ID138 90min 342 2.5 ID639 30min 364.9 2.6 
ID141 30min 345.9 2.6 ID639 90min 554.4 2.6 
ID141 90min 561.9 2.6 ID640 30min 339.6 2.5 
ID142 30min 260 2.5 ID640 90min 368.9 2.6 
ID142 90min 387 2.6 ID707 30min 1356.5 2.8 
ID144 30min 519.9 2.6 ID707 90min 410.6 2.7 
ID144 90min 264.1 2.5 ID708 30min 514.2 2.9 
ID145 30min 1545.1 3.1 ID708 90min 413.7 2.9 
ID145 90min 1797.5 3.3 ID709 30min 201 2.2 
ID146 30min 624.2 2.6 ID709 90min 556 2.9 
RIN, RNA integrity number 
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Supplemental table 2. MicroRNA intra-assay variability 
microRNA CV (%) 
cel-miR-39 0.86 
miR-425-5p 0.99 
miR-155-5p 0.43 
miR-181a-5p 1.47 
miR-877-5p 3.97 
miR-1 4.14 
miR-133b 2.53 
CV, coefficient of variability 
 
 
 
 
 
 
 
Supplemental table 4. Correlation between miR-1 and miR-133b* 
Time point post-PPCI  Spearman’s r P-value 
30 min 0.934 < 0.0001 
90min 0.949 < 0.0001 
* Correlation based on miRNA fold-change to controls  
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